Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study

Autor: Westers, T., Alhan, C., Van der Vorst, M., Chamuleau, M., Eeltink, C., Ossenkoppele, G., van de Loosdrecht, A.

Publikováno v: In Leukemia Research 2009 33 Supplement 1:S83-S83

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

Autor: Alhan, C., Westers, T.M., Helm, L.H. van der, Eeltink, C., Huls, G.A., Witte, B.I., Buchi, F., Santini, V., Ossenkoppele, G.J., Loosdrecht, A.A. van de

Publikováno v: Cytometry Part B. Clinical Cytometry, 86(3), 207-215. Wiley-Liss Inc.
Cytometry. Part B-Clinical Cytometry, 86, 207-15
Alhan, C, Westers, T M, van der Helm, L H, Eeltink, C M, Huls, G, Witte, B I, Buchi, F, Santini, V, Ossenkoppele, G J & van de Loosdrecht, A A 2014, ' Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes ', Cytometry Part B. Clinical Cytometry, vol. 86, no. 3, pp. 207-215 . https://doi.org/10.1002/cyto.b.21160
Cytometry. Part B-Clinical Cytometry, 86, 3, pp. 207-15

Item does not contain fulltext BACKGROUND: In intermediate-2 (Int-2) and high risk patients with myelodysplastic syndromes (MDS), treatment with azacitidine is associated with hematological improvement and prolonged overall survival (OS) in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::68b9f920ee0493363493c9ba4571ec0f
https://research.vumc.nl/en/publications/fa6156ba-fb14-4ffc-ab5f-45e0ef732745

A randomized clinical trial on the effectiveness of an intervention to treat psychological distress and improve quality of life after autologous stem cell transplantation.

Autor: Braamse, Annemarie, Meijel, B., Visser, O., Boenink, A., Cuijpers, P., Eeltink, C., Hoogendoorn, A., Marwijk Kooy, M., Oppen, P., Huijgens, P., Beekman, A., Dekker, J., Braamse, Annemarie M J, van Meijel, B, Visser, O J, Boenink, A D, Eeltink, C E, Hoogendoorn, A W, van Marwijk Kooy, M, van Oppen, P

Publikováno v: Annals of Hematology; Jan2016, Vol. 95 Issue 1, p105-114, 10p